The Nomination Committee of Ascelia Pharma AB (publ) (“Ascelia Pharma” or the “Company”) (Nasdaq Stockholm: ACE) proposes that Marianne Kock is elected as new member of the board of directors at an extraordinary general meeting in the Company to be held on 30 October 2024. The notice of the extraordinary general meeting will be published through a separate press release.

With a strong background as an executive in companies in the pharmaceutical industry, the Nomination Committee expects that Marianne Kock will add valuable skills to the board of directors, thus contributing to the future development of Ascelia Pharma.
 
“We are very happy to welcome Marianne Kock to the board of directors of Ascelia Pharma. She brings a wealth of global industry experience and her extensive background in development of pharmaceutical products and in regulatory affairs, including product approval by the FDA and EMEA, will be highly valuable as we continue to advance Orviglance to patients and grow Ascelia Pharma”, says Peter Benson, chairman of the board of directors.
 
Marianne has extensive experience from Ferring Pharmaceuticals A/S and Novo Nordisk where she has held senior positions and as board member in several small biotech companies. After spending 18 years at Novo Nordisk, where she took a product from research to launch and later as Vice President of Regulatory Support world-wide, she joined Ferring Pharmaceuticals in 2002.  She first served as Senior Vice President of Global Regulatory Affairs where she also started all development activities in Japan and China. During this period, she and her teams held several meetings with Regulatory Authorities world-wide. Later she was appointed General Manager for Ferring Pharmaceuticals A/S and where she is now chairperson of the board of directors. She is inter alia also a board member of the Danish Chamber of Commerce (Dansk Erhverv).
 
“There is a tremendous unmet need for better treatment for patients with rare cancer conditions, and Ascelia Pharma has a promising pipeline in this space. I look forward to joining the board of directors in Ascelia Pharma to support the mission of bringing better products to these patients”, says Marianne Kock.
 
The election of Marianne Kock as a new member of the board of directors is subject to resolution by an extraordinary general meeting in the Company to be held on 30 October 2024. The notice of the extraordinary general meeting will be published through a separate press release and the Nomination Committee’s full proposal will be available at the Company's website.

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

Contacts

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: jwb@ascelia.com
Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

Attachments

Ascelia Pharma Announces Proposal for Election of Marianne Kock as New Member of the Board of Directors